Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This is a prospective, multicenter, non-randomized, open-label, phase II study to describe
the efficacy of R-CHOP plus copanlisib including a safety run-in phase in order to detect
early and common unexpected toxicities caused by the addition of copanlisib to the standard
immuno-chemotherapy R-CHOP in patients with diffuse large B-cell lymphoma (DLBCL)